Early access to medicines scheme (EAMS) scientific opinion: Alectinib as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)
EAMS scientific opinion given to Roche Products Limited for alectinib as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), including the public assessment report.
Documents
Details
This positive scientific opinion was issued to Roche Products Limited for alectinib as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
This scientific opinion includes a public assessment report and a treatment protocol:
- for healthcare professionals
- for patients
- on the pharmacovigilance system
- EAMs scientific opinion – background information for Medical Directors
Contact
Information and details regarding patient access
For new patients wishing to access EAMS medicines in England, trusts must register patients on the NHS England web based registration system. Queries to NHS England regarding the scheme can be submitted to england.eams@nhs.net.
For information about access in Northern Ireland, contact Mark Timoney, Chief Pharmaceutical Officer at Mark.Timoney@dhsspsni.gsi.gov.uk and Joe Magee, Secondary Care Directorate at Joe.Magee@dhsspsni.gov.uk.
For information about access in Scotland contact the Scottish Government Directorate General Health & Social Care email John.Hannah@gov.scot and Elisabeth.Campbell@gov.scot.
For information about access in Wales, contact the Welsh Government Department of Health and Social Services by emailing Andrew Evans, Interim Chief Pharmaceutical Officer at Andrew.Evans@wales.gsi.gov.uk and Karen Eveleigh, Head of Pharmacy and Prescribing policy at Karen.Eveleigh@wales.gsi.gov.uk.